@article {Laverdi{\`e}re1127, author = {Isabelle Laverdi{\`e}re and Patrick Caron and Mario Harvey and {\'E}ric L{\'e}vesque and Chantal Guillemette}, title = {In Vitro Investigation of Human UDP-Glucuronosyltransferase Isoforms Responsible for Tacrolimus Glucuronidation: Predominant Contribution of UGT1A4}, volume = {39}, number = {7}, pages = {1127--1130}, year = {2011}, doi = {10.1124/dmd.111.039040}, publisher = {American Society for Pharmacology and Experimental Therapeutics}, abstract = {Tacrolimus (Tacro) is a potent immunosuppressant and a central agent in the prevention of posttransplantation rejection. Tacro is characterized by a narrow therapeutic index and wide interindividual pharmacokinetic fluctuation. The contribution of human UDP-glucuronosyltransferase (UGT) in its metabolism has not been extensively studied. In vitro metabolism studies support that the liver produced Tacro-glucuronide (Tacro-G) while its formation was minimal or undetectable in the presence of intestine and kidney microsomes. Among 16 human UGTs tested, UGT1A4 was the sole enzyme involved in Tacro-G formation. This conclusion is supported by the finding of inhibition with a specific substrate of UGT1A4 lamotrigine with Ki values similar for both human liver and UGT1A4 microsomes and the correlation with trifluoperazine-glucuronide formation by liver microsomes (rs = 0.551; p = 0.02). Formation of Tacro-G by liver samples varied among individuals (6.4-fold variation; n = 16), and common nonsynonymous variants may contribute to this variability. In the human embryonic kidney 293 cellular model, no significant differences in enzyme kinetics could be revealed for UGT1A4*2 (P24T) and *3 (L48V), whereas the allozyme *4 (R11W) displayed a 2-fold higher velocity (p \< 0.01) compared with the UGT1A4*1 enzyme preparation. In human liver samples, carriers of the UGT1A4 variants did not display statistically different efficiency in Tacro-G formation compared with homozygote for the reference genotype UGT1A4*1/*1. We conclude that UGT1A4 is the major isoform involved in Tacro glucuronidation, whereas additional studies are required to assess the contribution of UGT1A4 genetic factors in tacrolimus glucuronidation variability.}, issn = {0090-9556}, URL = {https://dmd.aspetjournals.org/content/39/7/1127}, eprint = {https://dmd.aspetjournals.org/content/39/7/1127.full.pdf}, journal = {Drug Metabolism and Disposition} }